Jeffrey Lancet, MD, discusses the findings from a phase III trial of CPX-351 versus 7+3 in older patients with high-risk, secondary acute myeloid leukemia
CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?
Recent Articles
Normal Results on D-Dimer Testing Can Safely Rule out Deep Vein Thrombosis
A simplified approach of an initial stand-alone D-dimer test followed by a single whole-leg compression ultrasound (CUS) in D-dimer positive patients can effectively and...
Highlights of ASH® Goes Virtual, Trainee Awards for Underrepresented Minorities, and more
Highlights of ASH® Goes Virtual
Each year, the American Society of Hematology’s (ASH’s) Highlights of ASH® meeting series offers a synopsis of the top hematology...
Leaving the Bedside
Career opportunities for doctors extend far beyond the patient care setting.
When choosing to become a physician, most people expect to spend their entire working...
Safe Pain Management With Opioid Therapy
This month, Holly L. Geyer, MD; Halena Gazelka, MD; and Ruben Mesa, MD, provide a case-based discussion of how to manage pain safely with...
Investing in the Future: An Interview With Judith Gasson, PhD
Judith Gasson, PhD, the 2020 ASH Mentor Award recipient for basic science, shares her three simple rules for running a lab and her thoughts...
Current Issue
December 2020, Volume 6, Issue 15
This issue explores non-clinical career opportunities for doctors, hematologic concerns for transgender patients, and more.